Chronic Pruritus Therapeutics Market Size Projected To Reach 14.49 Billion By 2034 With A Cagr Of 7.3%

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Projected Growth of the Chronic Pruritus Therapeutics Market?
In recent times, the market size of chronic pruritus therapeutics has experienced significant growth. The market is projected to rise from its size of $10.17 billion in 2024 to $10.94 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 7.6%. The growth during the historic period is due to various factors such as an increased occurrence of chronic pruritus, elevated demand for potent treatments, expanded regulatory clearances, an uptick in product endorsements, and a surge in mergers, collaborations, and acquisitions among industry participants.

In the upcoming years, the chronic pruritus therapeutics market is predicted to witness substantial growth, expanding to a size of $14.49 billion in 2029 with a compound annual growth rate (CAGR) of 7.3%. Factors contributing to the growth during the forecast period include increasing awareness, a rise in atopic dermatitis incidence, a heightened emphasis on personalized treatments, escalated rates of skin conditions, and a growing number of patients. The forecasting period will also see several transformative trends including the launch of innovative medicines, the creation of new biologics and targeted therapies, advancements in technology, the inclusion of advanced drug delivery systems, partnerships between pharmaceutical companies and research bodies, as well as the adoption of digital health technologies such as telemedicine.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147

What Are the Different Chronic Pruritus Therapeutics Market Segments?
The chronic pruritus therapeutics market covered in this report is segmented -

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types
2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types
3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:
1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics
4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants
5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy
7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

What Are the Primary Drivers Shaping the Chronic Pruritus Therapeutics Market?
The increase in cases of atopic dermatitis is projected to accelerate the expansion of the chronic pruritus therapeutics market. Atopic dermatitis (AD) is a long-term skin disease characterized by inflammation, redness, itching, and dryness, primarily affecting individuals with a familial predisposition to allergies, asthma or hay fever. The heightened occurrences of atopic dermatitis arise from factors like genetic tendencies, environmental shifts, variations in lifestyle, the hygiene hypothesis, intensified exposure to allergens, and irregularities in the skin microbiome. Therapeutics for chronic pruritus work to relieve the relentless itchiness connected with atopic dermatitis by addressing the root inflammatory pathways, lessening skin irritation, and enhancing patient comfort. For example, the International Eczema Council, a nonprofit organization based in the US, reported in 2022 that an estimated 223 million people worldwide had atopic dermatitis (GBD 2022), including 43 million children aged between 1-4, indicating the disease's substantial incidence in early childhood. Consequently, the escalating prevalence of atopic dermatitis is fueling the growth of the chronic pruritus therapeutics market.

Which Companies Are Leading in the Chronic Pruritus Therapeutics Market?
Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

What Trends Are Expected to Dominate the Chronic Pruritus Therapeutics Market in the Next 5 Years?
Key players in the chronic pruritus therapeutics market are concentrating their efforts on creating novel formulations, such as intravenous (IV) injections, to improve treatment outcomes and provide quicker relief for patients. IV injections are effective in treating pruritus because they deliver medications like antihistamines or corticosteroids straight into the bloodstream to promptly relieve itching and lessen inflammation. For example, in September 2023, Cara Therapeutics Inc., a US-based therapeutics manufacturer, revealed that its associated company, Maruishi Pharmaceutical Co. Ltd, a Japan-based pharmaceutical firm, had been granted approval by Japan's Ministry of Health, Labour and Welfare for the Korsuva IV injection syringe, which is a pruritus treatment for hemodialysis patients. This endorsement was predicated on the positive outcomes of a Phase 3 clinical trial undertaken by Maruishi in partnership with Kissei Pharmaceutical Co., Ltd. The treatment demonstrated considerable improvements in itching scores against a placebo and was well received by patients. The approval also initiated a $1.5 million milestone payment to Cara Therapeutics, Korsuva's developer, in line with the terms of their licensing agreement with Maruishi.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

What Are the Top Revenue-Generating Geographies in the Chronic Pruritus Therapeutics Market?
North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Chronic Pruritus Therapeutics Market?
2. What is the CAGR expected in the Chronic Pruritus Therapeutics Market?
3. What Are the Key Innovations Transforming the Chronic Pruritus Therapeutics Industry?
4. Which Region Is Leading the Chronic Pruritus Therapeutics Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.